Bayer's Asundexian FXIa Inhibitor Reduces Ischemic Stroke in OCEANIC-STROKE Study

The phase 3 trial found asundexian lowered risk of ischemic stroke and major cardiovascular events without increased major bleeding.

Apr. 17, 2026 at 9:02pm

Got story updates? Submit your updates here. ›

A highly detailed, ghostly X-ray image revealing the complex internal structure of the human brain, with glowing neural pathways and blood vessels, conceptually illustrating the importance of preventing ischemic stroke.An innovative new stroke prevention therapy aims to reduce the devastating impact of ischemic brain damage.New Orleans Today

The results of the OCEANIC-STROKE study, published in The New England Journal of Medicine, showed that Bayer's investigational oral factor XIa inhibitor asundexian reduced the incidence of ischemic stroke, major cardiovascular events, and adverse events compared to placebo in patients after a noncardioembolic ischemic stroke or high-risk transient ischemic attack.

Why it matters

The OCEANIC-STROKE findings suggest asundexian could be a promising new treatment option to help prevent recurrent ischemic stroke in high-risk patients, addressing an important unmet medical need. The reduction in major cardiovascular events without an increase in major bleeding is particularly noteworthy.

The details

The multicenter, international, randomized, double-blind, placebo-controlled, phase 3 OCEANIC-STROKE trial enrolled 12,327 patients and compared asundexian 50 mg once daily plus antiplatelet therapy to placebo plus antiplatelet therapy. The primary efficacy outcome was incidence of ischemic stroke, which was 6.2% with asundexian versus 8.4% with placebo. The primary safety outcome of major bleeding was 1.9% with asundexian versus 1.7% with placebo.

  • The OCEANIC-STROKE study results were published on April 17, 2026 in The New England Journal of Medicine.
  • The initial data from the OCEANIC-STROKE study were presented on February 5, 2026 at the American Heart Association's International Stroke Conference in New Orleans, Louisiana.

The players

Mukul Sharma, MD

The lead author of the OCEANIC-STROKE study published in The New England Journal of Medicine.

Bayer

The pharmaceutical company that developed the investigational oral factor XIa inhibitor asundexian evaluated in the OCEANIC-STROKE trial.

Got photos? Submit your photos here. ›

What they’re saying

“The findings showed that compared to placebo, asundexian reduced the incidences of ischemic stroke; major bleeding; adverse events serious adverse events and the composite of death from cardiovascular causes, myocardial infarction, or stroke.”

— Mukul Sharma, MD, Lead Author

What’s next

Asundexian is an investigational compound and has not been approved by any health authority for use in any country for any indication. Further clinical development and regulatory review will be required before asundexian could potentially become available as a new treatment option.

The takeaway

The positive results from the OCEANIC-STROKE trial suggest asundexian could be an important new therapy to help prevent recurrent ischemic stroke in high-risk patients, with the potential to reduce both cardiovascular events and bleeding complications.